Unknown

Dataset Information

0

Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer.


ABSTRACT: Tumor mRNA expression was used to discover genes associated with worse survival or no survival benefit after intraperitoneal (IP) chemotherapy. Data for high grade serous ovarian cancer patients treated with IP (n = 90) or IV-only (n =? 398) chemotherapy was obtained from The Cancer Genome Atlas. Progression free survival (PFS) and overall survival (OS) were compared between IP and IV groups using Kaplan-Meier analysis and Cox regression. Validations were performed by analyses of microarray and RNA-Seq mRNA expression data. PFS and OS were compared between IP and IV groups by permutation testing stratified by gene expression. P-values are two-tailed. IP chemotherapy increased PFS (26.7 vs 16.0 months, HR 0.43 (0.28-0.66), p = 0.0001) and OS (49.6 vs 38.2 months, HR 0.46 (0.25-0.83), p = 0.01). Increased expression of NCAM2 and TSHR and decreased expression of GCNT1 was associated with decreased PFS and OS after IV chemotherapy (p < 0.05). High tumor expression of LMAN2, FZD4, FZD5, or STT3A was associated with no significant PFS increase after IP compared to IV chemotherapy. Low expression of APC2 and high expression of FUT9 was associated with 5.5 and 7.2 months, respectively, decreased OS after IP compared to IV chemotherapy (p ? 0.007).

SUBMITTER: Seagle BL 

PROVIDER: S-EPMC4756718 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer.

Seagle Brandon-Luke L BL   Eng Kevin H KH   Yeh Judy Y JY   Dandapani Monica M   Schiller Emily E   Samuelson Robert R   Odunsi Kunle K   Shahabi Shohreh S  

Scientific reports 20160217


Tumor mRNA expression was used to discover genes associated with worse survival or no survival benefit after intraperitoneal (IP) chemotherapy. Data for high grade serous ovarian cancer patients treated with IP (n = 90) or IV-only (n =  398) chemotherapy was obtained from The Cancer Genome Atlas. Progression free survival (PFS) and overall survival (OS) were compared between IP and IV groups using Kaplan-Meier analysis and Cox regression. Validations were performed by analyses of microarray and  ...[more]

Similar Datasets

| S-EPMC7168334 | biostudies-literature
| S-EPMC4554746 | biostudies-other
| S-EPMC8508040 | biostudies-literature
| S-EPMC7812203 | biostudies-literature
| S-EPMC6162496 | biostudies-literature
| S-EPMC5310690 | biostudies-literature
| S-EPMC4164826 | biostudies-literature
| S-EPMC8602974 | biostudies-literature
| S-EPMC6602817 | biostudies-literature
| S-EPMC8272440 | biostudies-literature